Vendor source

Reviewed 11 May 2026

Completeness Strong (75%)

MammoScreen®

Therapixel

MammoScreen helps radiologists to identify findings on screening mammograms and assess their level of suspicion. MammoScreen® uses a color coded MammoScreen Score™ to provide an at a glance level-of-suspicion scoring for screening mammograms; confirming the lowest and highest scores (the green and red cases, respectively for the lowest and highest suspicion categories), and emphasizing those that require deeper scrutiny (the yellow cases, for the indeterminate category).

Supported by 2 papers

Key Features

  • Lesion detection and characterization
  • Level-of-suspicion score

General Information

Product name

MammoScreen®

Company

Modality

Mammography

Main task

Not specified

Subspeciality

Breast

Disease targeted

Breast cancer

Regulatory Information

CE Certification

Pathway:

MDD

Class:

Class IIa

Verified by Health AI Register

FDA Certification

Pathway:

510(k) cleared

Class:

Class II

Verified by Health AI Register

Other certifications

Not specified

Technical Specifications

Patient population age

Not specified

Input

Screening DBT & FFDM, prior images if available

Input format

DICOM

Output

Visual report with detected and assessed lesions

Output format

Web interface or DICOM SC or DICOM SR.

Integration

Integration via AI marketplace or distribution platform, Stand-alone webbased

Deployment

Cloud-based

Trigger for analysis

Automatically, right after the image acquisition

Processing time

Not specified

Population

Screening mammography

Market Presence

On market since

FFDM FDA 05-2020 FFDM CE 12-2020 DBT CE 11-2021 DBT FDA 11-2021

Resellers

Milvue, Osimis, Qure.ai

Countries present

Not specified

Paying clinical customers

Not specified

Research/test users

Not specified

Pricing Information

Pricing model

Subscription

Based on

Not specified

Source: Vendor | First published: Jun 20, 2023 | Last updated: May 11, 2026